The board of directors of Huakang Biomedical Holdings Company Limited announced that, with effect from January 14, 2020, Mr. He Jiaming has been appointed as an executive Director. Mr. He joined the Group as a business development director in January 2019, and is responsible for evaluating and developing new products in connection with male fertility and exploring overseas business cooperation opportunities. Mr. He has over 4 years of experience in the fields of biochemistry and international trading prior to joining the Group. In relation to his new appointment as an executive Director, Mr. He will enter a service contract with the Company for an initial fixed term of three years commencing from the date of appointment and could be terminated by either party giving not less than three-months' notice. Mr. He shall hold office until the next following annual general meeting and shall then be eligible for re-election at that meeting and will be subject to retirement by rotation and re-election in accordance with the articles of association of the Company.